Background: The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors which has been linked with a decline in muscle mass. However, with a variety of sarcopenia definitions, it is unclear which approach is suitable to detect reduced muscle mass in subjects with MetS who are frequently characterized by an increased fat mass and higher body weight.
The metabolic syndrome (MetS) is an important cluster of at least three out of five cardiovascular risk factors (1) . Cardinal features of the MetS include dyslipidemia, abdominal obesity, hypertension, and insulin resistance and its prevalence increases with age.
Subjects with MetS frequently suffer from excess fat mass and higher visceral adipose tissue in particular. Moreover, increased degradation of muscle mass is observed in insulin resistance, as insulin and insulin-like growth factor 1 (IGF-1) are not only responsible for glucose uptake but also for the maintenance of muscle mass via stimulation of muscle protein synthesis and inhibition of muscle protein breakdown (2) (3) (4) (5) . Insufficient activation of the PI3K/Akt-pathway as a hallmark of insulin-(IGF-1) resistance is found in the MetS and accelerates breakdown of skeletal muscle (6) . On the other hand, lean and skeletal muscle mass may be reduced due to life style factors such as low physical activity.
In turn, reduced muscle mass may further aggravate metabolic impairment, since skeletal muscle is the primary site of glucose uptake and deposition. The MetS has therefore been linked to low muscle strength and performance, as well as loss of muscle mass (7) (8) (9) (10) (11) . Moreover, high metabolic load has been associated with poor muscle quality; for example, change in muscle fibers (12, 13) or fat infiltration in muscle, which are discussed to be major risk factors for the progression of disability and sarcopenia in ageing (14) (15) (16) (17) (18) (19) . Obesity and insulin resistance are thus considered predictors of disability (20) (21) (22) (23) (24) (25) (26) (27) .
Sarcopenia which refers to the loss of muscle mass occurring with age (28) has gained attention as risk factor for decreased physical ability, falls, and increased need for care and is highly prevalent in the old (29) (30) (31) (32) . The underlying mechanisms leading to sarcopenia are not yet fully understood but inflammation, neuromuscular, and hormonal changes as well as physical inactivity and nutrition are currently discussed (33, 34) .
In the last decade, several definitions of sarcopenia have been suggested to facilitate diagnosis both in clinical care and the ambulatory setting (28, 35) .
The aim of this cross-sectional analysis was to identify the most suitable method to diagnose sarcopenia in a cohort of communitydwelling old with a high prevalence of metabolic risk factors and MetS. We examined two previously published measures of sarcopenia, comparing the conventional approach (appendicular lean mass corrected for height ALM/HT 2 ); to the residuals approach where ALM is corrected both for height and weight, to account for the often higher weight in these subjects. We analyzed the association of both definitions with strength, mobility, and self-reported limitations in physical performance. Moreover, we investigated the impact of the two measures of sarcopenia on different metabolic parameters.
Patients and Method

Study Population and Design
One thousand four hundred and two older participants from the Berlin Aging Study II (BASE-II) recruited between 2009 and 2013 were included in this analysis. BASE-II is a prospective epidemiological study to investigate factors associated with "healthy" or "unhealthy" aging in the residents of the greater metropolitan area of Berlin, Germany as described previously (36) . In short, eligibility criteria at the time of recruitment were community dwelling, wellfunctioning older Caucasian subjects aged between 60 and 80 years. Participants were excluded if they (i) reported difficulty walking onequarter of a mile without assistance, (ii) suffered from Parkinson Disease, or had experienced stroke, myocardial infarct, (iii) undergone head, heart, or vascular surgery or (iv) suffered from dementia or malignant disease. All participants gave written informed consent and the Ethics Committee of the Charite Universitätsmedizin Berlin approved the study (approval number EA2/029/09).
Age, sex, current smoking status (yes/no) were documented. The comorbidity index was determined according to Charlson and colleagues (37), using the updated weights by Quan and coworkers (38) .
Metabolic Laboratory Parameters
Blood samples were collected after more than 8 hours overnight fasting. Glucose was assessed with photometric measurements. Serum triglycerides and high-density lipoprotein (HDL) cholesterol levels were assessed using enzymatic color tests and insulin levels by chemiluminescence immunoassay. Insulin resistance was calculated using fasting glucose and insulin levels in the homeostasis model of insulin resistance (HOMA-IR) as (fasting glucose (mg/dL) × fasting insulin (mU/mL))/405.
Metabolic Syndrome
MetS was defined as suggested by IDF/AHA/NHLBI 2009 (1). Participants with three out of five medical conditions were diagnosed with MetS. Those criteria are (i) high blood pressure (systolic blood pressure >130 mmHg and/or diastolic blood pressure > 85 mmHg or known hypertension), (ii) high triglycerides (triglyceride levels >150 mg/dL), (iii) abdominal obesity by waist circumference (>94 cm in men and >80 cm in women), insulin resistance (fasting glucose >100 mg/dL or known Type II Diabetes), or low serum HDL cholesterol (<40 mg/dL in men and 50 mg/dL in women).
Systolic and diastolic blood pressure were measured with an electronic sphygmomanometer (boso-medicus memory, Jung Willingen, Germany) after a 5-minute rest period in a sitting position on the left arm. The determination of waist circumference was carried out using a nonelastic tape measure midway between the costal arch and the iliac crest.
Body Composition and Sarcopenia
Body weight was measured in light clothes (to the nearest 0.1 kg and height was determined to the nearest 0.1 cm) using an electronic weighing and measuring station (seca 764, seca, Hamburg, Germany). Weight and height were used to calculate body mass index (BMI) (weight [kg]/height [m] 2 ). Body composition was assessed with DXA Hologic Discovery Wi (software APEX version 3.0.1). A trained technician performed the DXA measurement protocol. Appendicular lean mass (ALM) in kilograms was calculated as the sum of the nonbone lean mass in arms and legs and related to height (ALM/HT 2 , kg/m 2 ) (39). ALM was also corrected for weight (ALM/weight).
Self-reported Limitations in Physical Performance
Participants were asked whether they had difficulties performing moderate or exhausting activities (such as lifting heavy objects, walking fast, or running) or climbing several flights of stairs (severe/ moderate/no difficulties).
Muscle Strength and Timed "Up and Go" (TUG) Test
Maximal isometric hand grip strength was measured on the left hand side using a Smedley Dynamometer (Scandidact, Denmark). While performing the test the participants were standing and the shoulder was adducted and neutrally rotated, the elbow was flexed to 90º and the forearm and wrist were in neutral position. The participants were then asked to perform a maximal isometric contraction, and the highest out of three values was recorded. The TUG was performed as measure of mobility, as described by Podsiadlo and colleagues (40) .
Sarcopenia Definitions
Sarcopenia was defined using cut-offs suggested by Baumgartner et al. (39) : ALM/HT 2 ≤ 7.26 kg/m 2 in men and ≤5.5 kg/m 2 in women. In a second step, we corrected ALM for both height and weight following the approach suggested by Newman and coworkers (41). and, also recently by Dufour and associates (42) for an alternative definition of sarcopenia, by modeling the relationship between ALM on height (m) and weight (kg) with linear regression. Sarcopenia was defined by the residuals of the regression, with sarcopenia as < 20th percentile of calculated standardized residuals, identifying those subjects whose ALM was much lower than the predicted value. Models were fit for women: ALM 
Statistics
The statistical analysis was performed using IBM SPSS v21. Data are given in percent or as mean and standard deviation. Chi 2 test was used to compare frequencies between groups. All variables were tested for normal distribution according Kolmogorov-Smirnov Test. Students t test was used for normally distributed, Mann-Whitney U-Test for nonparametric variables to assess differences in mean or median. Standardized residuals were calculated with ALM as dependent variable according to a linear regression model, including weight and height as covariates. An acceptable level of statistical significance was established a priori at p < .05.
Results
Complete cross-sectional data on metabolic parameters, anthropometry, and body composition were available for 1,402 older subjects (51.1% female; 69 ± 3.7 years). 269 participants (19.2%) had one and 577 participants (41.2%) had two metabolic risk factors. MetS (≥ three out of five risk factors) was diagnosed in 35.5% of the subjects. Altogether, 95% of subjects had at least one metabolic risk factor. Mean Charlson comorbidity index was 0.85 ± 1.29, and was significantly higher in subjects with MetS (0.92 ± 1.33 vs 0.70 ± 1.18 in women, p = .045 and 1.10 ± 1.50 vs 0.75 ± 1.17 in men, p = .02.) Altogether, the number of diseases was too small to detect any significance between the sarcopenia definitions. Table 1 displays clinical characteristics of the participants according to MetS and sex. Elevated waist circumference (80.4% of the participants) and elevated blood pressure (84.6% of the participants) were the most frequent parameters leading to the diagnosis of MetS. Men were more often diagnosed with MetS, were more frequently current smokers and reported fewer limitations in performing physical activities than women.
Fat mass, BMI, and waist circumference were significantly higher in subjects with MetS (p < .001). However, absolute ALM and ALM/HT 2 were also higher in male and female subjects with MetS (p < .001). As anticipated, metabolic load, represented by fasting glucose, HOMA-IR, triglyceride and HDL levels as well as systolic and diastolic blood pressure, was increased in subjects with MetS, independent of sex (data not shown). Participants with MetS reported limitations in physical activities such as, for example, climbing several stairs more frequently (Table 1) . When correcting ALM for weight, both men and women with MetS consistently exhibited lower values (See Table 1 ). Neither grip strength nor TUG time were relevantly impaired in participants with MetS.
Sarcopenia According to Method
According to the approach suggested by Baumgartner and coworkers (reduced ALM/HT 2 ), 25.6% of the study population had sarcopenia. Defining sarcopenia by regression residuals (ie, lower ALM than predicted for a certain height and weight), 20% of the subjects were detected as sarcopenic (≤ 20th percentile). Only 56% of the subjects defined sarcopenic by ALM/HT 2 were also defined sarcopenic by the residuals approach (See Figure 1) .
Reduced ALM/HT 2
As shown in Table 2 and 3, subjects defined sarcopenic by low ALM/HT 2 had a lower BMI and lower fat mass. Although grip strength and TUG time were lower in the sarcopenic participants, self-reported limitations in physical performance did not occur more frequently in these subjects. Moreover, sarcopenic participants were less likely to have metabolic impairments. Waist circumference, fasting glucose, HOMA-IR and triglyceride levels were even significantly lower, and HDL levels were significantly higher in participants with a low ALM/HT 2 , as shown in Tables 2 and 3 .
Residuals from Linear Regression
In contrast, participants deemed sarcopenic according to the residuals approach exhibited significantly higher fat mass and lower ALM and ALM/HT 2 than nonsarcopenic individuals, with comparable values for BMI and waist circumference. Both grip strength and TUG time were impaired in sarcopenic participants and sarcopenic women in particular, reported difficulties in physical performance significantly more often, whereas sarcopenic men only reported difficulties with strenuous physical activity. Sarcopenia by residuals showed a nonsignificant trend towards a higher prevalence of MetS in men and women. Regarding parameters of MetS, HOMA-IR, fasting insulin, and waist circumference were significantly higher in sarcopenic participants according to the residual approach.
Comparison Between Sarcopenia According to ALM/HT 2 Versus Residuals
When comparing the two operational parameters, the majority of physical and metabolic parameters were impaired and limitations in performing physical activities occurred more frequently in individuals defined sarcopenic according to residuals than in subjects with a low ALM/HT 2 as shown in Tables 2 and 3 and Figure 2 . Most strikingly, prevalence of MetS in sarcopenic individuals was nearly twice as high when using the residuals approach.
Discussion
We compared two methods to diagnose sarcopenia in communitydwelling old, of whom 95% fulfilled at least one cardiovascular risk factor included in the definition of the MetS. In the current analysis we found that sarcopenia defined by a low ALM/HT 2 , in which ALM is related to height, was not associated with impaired physical performance. More importantly, sarcopenic subjects exhibited a lower metabolic risk profile and were consequently less often suffering from MetS than nonsarcopenic participants. This is with all probability due to the fact that participants with low ALM/HT 2 are leaner than nonsarcopenic subjects, which is usually associated with lower metabolic load in this Notes: ALM = appendicular lean mass; BMI = body mass index; HDL = high-density lipoprotein; HOMA-IR = homeostasis model of insulin resistance. Notes: ALM = appendicular lean mass; BMI = body mass index; HDL = high-density lipoprotein; ; HOMA-IR = homeostasis model of insulin resistance.
cohort with high metabolic impairment. Using ALM/HT 2 underestimates the prevalence of reduced muscle mass in individuals with overweight or abdominal obesity, which has been shown before (41, 43) .
Using the residual approach to define sarcopenia, in which ALM is corrected for both height and weight however, we found both higher metabolic load and impaired physical performance more frequently in sarcopenic subjects compared to nonsarcopenic subjects. Also, when comparing the two operational definitions, subjects deemed sarcopenic according to residuals approach reported limitations in physical performance more frequently than subjects deemed sarcopenic according to low ALM/HT 2 . In the last decades, various working groups have searched for the ideal approach to define sarcopenia, combining low muscle mass and low muscle strength in order to obtain a suitable method to detect subjects at increased risk of physical decline.
However, most sarcopenia definitions are designed for an aged population with a high risk for physical disability. In our analysis, we focused on physically independent, community-dwelling subjects with a mean age of 68 who exhibited a high prevalence of metabolic impairments and MetS. Diagnosing sarcopenia is challenging in this group as higher body weight and higher fat mass and thus potentially higher lean body mass will make it less likely for the participants to fall below predefined ALM/HT 2 cutoff points. The fact that ALM increases with increasing weight therefore needs to be taken into account when trying to identify sarcopenia in subjects with higher BMI (for an extensive review see (44) ). Using the residual modeling approach with sex-, weight-, and heightadjusted cutoffs allows identification of subjects with a disproportionately low ALM in higher BMI categories. An overestimation of sarcopenia in obese subjects is unlikely, and certainly not to the extent of the underestimation of sarcopenia in overweight and obese subjects using the conventional method (low ALM/HT 2 ). However, as insulin resistance increases the risk of muscle breakdown and proteolysis and low muscle mass in turn aggravates insulin resistance (45) , reliable identification of sarcopenia is of major relevance in patients with metabolic risk factors. Lee and colleagues found significantly higher loss of lean mass over a period of 4.6 years in insulin resistant men from the "Osteoporotic Fractures in Men" study despite a higher absolute lean mass at baseline, which was accompanied by a higher fat mass (27) . Ideally, detection of reduced muscle mass should occur early in order to introduce lifestyle or medical intervention (9), as high muscle mass and strength have been shown to be protective factors in the development of MetS (9) . Clearly, using ALM/HT 2 cutoffs in this population is unsuitable to detect subjects who might be at higher risk of metabolic impairment due to low muscle mass. Correcting ALM for weight, however, Moon and coworkers (46) found an association between reduced muscle mass and metabolic risk factors such as insulin resistance and MetS in subjects with a BMI < 27.5 kg/m 2 . Volpato et al. (47) found reduced muscle quality in subjects with prevalent type 2 diabetes to be associated with reduced gait speed and reduced muscle strength, despite greater calf muscle area.
As our data stem from a cross-sectional study, we cannot differentiate between primary, age-related sarcopenia, and secondary sarcopenia in our study participants. It is likely, that secondary sarcopenia, resulting from, for example, a sedentary lifestyle or inflammation, is more common in our study population, but our data allow no conclusion on cause and effect. A further limitation of our study is that only TUG, was available as a measure of mobility. Ideally, gait speed and short battery performance tests should be determined in order to validate our findings.
In conclusion, other measures of low ALM and sarcopenia definitions have to be used in this special cohort of patients with insulin resistance or MetS, whose overweight frequently impedes early detection of inadequate muscle mass with the conventional approach. They are, however, at increased risk for muscle mass breakdown, fat infiltration in muscle, or changes in muscle fibers. The residual modeling approach which adjusts ALM for both weight and height seems to be more reliable to detect sarcopenia in MetS, as it is associated with greater metabolic load and lower physical performance. Moreover, it might also be suitable to predict future risk for physical disabilities in these subjects.
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